Thomas Cannell, Sesen Bio CEO
July 18, 2022 10:40 AM EDTUpdated 11:06 AM
R&D

Sesen Bio paus­es blad­der can­cer drug work, of­floads eye dis­ease an­ti­bod­ies to Roche

Lei Lei Wu

News Reporter

Fol­low­ing an FDA re­jec­tion last year, Sesen Bio an­nounced this morn­ing that it will be paus­ing de­vel­op­ment on its lead blad­der can­cer drug.

With the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times